Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
Author:
Open Access
- 19 December 2014
- journal article
- review article
- Published by BioExcel in Drugs in Context
- Vol. 3, 1-19
Abstract
Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce complications. This article reviews the evidence from clinical trials and suggests that SGLT2 inhibitors are a promising new treatment option for T2DM.Keywords
This publication has 65 references indexed in Scilit:
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Diabetes & Endocrinology, 2013
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 DiabetesDiabetes Care, 2013
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia, 2013
- Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozinJournal of Diabetes and its Complications, 2013
- Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 yearsDiabetes, Obesity and Metabolism, 2013
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metforminDiabetes, Obesity and Metabolism, 2013
- Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized TrialHospital Practice, 2013
- Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsDiabetes, Obesity and Metabolism, 2011
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implicationsDiabetic Medicine, 2010
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy SubjectsClinical Pharmacology & Therapeutics, 2009